Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
BioNTech posts overall survival data on would-be Keytruda killer
BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial benchmark and supporting use in a broader population.
Nick Paul Taylor
Dec 10, 2024 9:00am
Engineered yeast delivers PD-1 inhibitors, shrinks mice tumors
Nov 22, 2024 3:12pm
Sensei lays off 46% of staff, closes site to fund cancer trial
Nov 14, 2024 9:38am
BioNTech pays $800M to take control of potential Keytruda killer
Nov 13, 2024 6:45am
Crescent inks GlycoMimetics merger, securing listing and $200M
Oct 29, 2024 10:20am
Merck's LAG-3 combo fails colorectal cancer phase 3 study
Sep 25, 2024 8:35am
